These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12953938)

  • 21. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
    Errante D; Bernardi D; Bianco A; De Nardi S; Salvagno L
    Ann Oncol; 2006 Nov; 17(11):1720-1. PubMed ID: 16731537
    [No Abstract]   [Full Text] [Related]  

  • 22. [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].
    Abasq C; Duval-Modeste AB; Courville P; Joly P
    Ann Dermatol Venereol; 2008; 135(6-7):509-11. PubMed ID: 18598807
    [No Abstract]   [Full Text] [Related]  

  • 23. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).
    Aboulafia DM
    Am J Clin Oncol; 2001 Jun; 24(3):237-40. PubMed ID: 11404492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].
    Gamo R; Calzado L; Pinedo F; López-Estebaranz JL
    Actas Dermosifiliogr; 2008 May; 99(4):291-6. PubMed ID: 18394405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary cutaneous B-cell lymphomas.
    Kempf W; Denisjuk N; Kerl K; Cozzio A; Sander C
    J Dtsch Dermatol Ges; 2012 Jan; 10(1):12-22; quiz 23. PubMed ID: 22212142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
    Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
    Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant angioendotheliomatosis is an angiotropic intravascular lymphoma. Immunohistochemical, ultrastructural, and molecular genetics studies.
    Perniciaro C; Winkelmann RK; Daoud MS; Su WP
    Am J Dermatopathol; 1995 Jun; 17(3):242-8. PubMed ID: 8599432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
    Horváth B; Demeter J; Eros N; Hársing J; Csomor J; Matolcsy A; Bottlik G; Gyori G; Marschalkó M; Kárpáti S
    J Am Acad Dermatol; 2009 Nov; 61(5):885-8. PubMed ID: 19632742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.
    Massengale WT; McBurney E; Gurtler J
    J Am Acad Dermatol; 2002 Mar; 46(3):441-3. PubMed ID: 11862185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focal rituximab-induced edematous reaction at primary cutaneous follicle center lymphoma lesions: case report and literature review.
    Brunet-Possenti F; Franck N; Tamburini J; Jacobelli S; Avril MF; Dupin N
    Dermatology; 2011; 223(3):200-2. PubMed ID: 21986026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cutaneous marginal zone B-cell lymphoma treated with rituximab].
    Pedraz J; Delgado Y; Aragüés M; Fraga J; García-Díez A; Fernández-Herrera J
    Actas Dermosifiliogr; 2005 Nov; 96(9):593-7. PubMed ID: 16476304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anti-CD20 antibodies in primary cutaneous B-cell lymphoma. Initial results in dermatologic patients].
    Gellrich S; Muche JM; Pelzer K; Audring H; Sterry W
    Hautarzt; 2001 Mar; 52(3):205-10. PubMed ID: 11284065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.
    Clarke LE; Bayerl MG; Ehmann WC; Helm KF
    J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.
    Heinzerling L; Dummer R; Kempf W; Schmid MH; Burg G
    Arch Dermatol; 2000 Mar; 136(3):374-8. PubMed ID: 10724200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
    Tobinai K
    Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit.
    Esmaeli B; Murray JL; Ahmadi MA; Naderi A; Singh S; Romaguera J; White CA; McLaughlin P
    Arch Ophthalmol; 2002 Sep; 120(9):1225-7. PubMed ID: 12215104
    [No Abstract]   [Full Text] [Related]  

  • 38. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
    Hao LC; Zhang LZ
    Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
    [No Abstract]   [Full Text] [Related]  

  • 40. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
    Morales AV; Advani R; Horwitz SM; Riaz N; Reddy S; Hoppe RT; Kim YH
    J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.